Cell culture models of neuronal degeneration and neuroprotection: Implications for Parkinson's disease
ET Kokotos Leonardi, C Mytilineou - Molecular and Cellular Mechanisms …, 1998 - Springer
ET Kokotos Leonardi, C Mytilineou
Molecular and Cellular Mechanisms of Neuronal Plasticity: Basic and Clinical …, 1998•SpringerParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive
loss of dopaminergic neurons in the substantia nigra (McGeer, et al., 1988). The disease has
a late onset, and is fairly prevalent, affecting 1% of the general population over the age of 50
(Polymeropoulos, et al., 1996). Treatment for the disorder is largely symptomatic, usually
beginning with dopaminergic agonist therapy, or with a combination of levo-dopa (L-DOPA)
and dopaminergic receptor agonists (see Rabey, 1995 and Corboy et al., 1995 for review).
loss of dopaminergic neurons in the substantia nigra (McGeer, et al., 1988). The disease has
a late onset, and is fairly prevalent, affecting 1% of the general population over the age of 50
(Polymeropoulos, et al., 1996). Treatment for the disorder is largely symptomatic, usually
beginning with dopaminergic agonist therapy, or with a combination of levo-dopa (L-DOPA)
and dopaminergic receptor agonists (see Rabey, 1995 and Corboy et al., 1995 for review).
Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra (McGeer, et al., 1988). The disease has a late onset, and is fairly prevalent, affecting 1% of the general population over the age of 50 (Polymeropoulos, et al., 1996). Treatment for the disorder is largely symptomatic, usually beginning with dopaminergic agonist therapy, or with a combination of levo-dopa (L-DOPA) and dopaminergic receptor agonists (see Rabey, 1995 and Corboy et al., 1995 for review).
Springer
